Axsome Therapeutics, Inc. (AXSM) SEC Filings & Earnings Calls

Accumulated deficit and ongoing losses

“As of June 30, 2026, the Company had an accumulated deficit of $1,421.8 million.” · word for word

SG&A expense growth outpacing revenue growth

“Selling, general and administrative $208,137 (Q2 2026) vs $130,280 (Q2 2025), a 60% increase.”

Concentration of credit risk

“At June 30, 2026, the majority of the Company's cash was held by two financial institutions.” · word for word

Increasing SG&A expenses due to commercialization activities

“SG&A expenses were $208.1 million for Q2 2026, compared to $130.3 million for Q2 2025, increase primarily reflects commercialization activities for AUVELITY and SYMBRAVO.” · word for word

Net loss persists despite revenue growth

“Net loss of $51.3 million in Q2 2026, compared to $48.0 million in Q2 2025.”

Patent litigation risk resolved; no further financial exposure from this case.

“Settlement resolves all SUNOSI patent litigation.”

Concentration risk on AUVELITY (80% of product revenue).

“AUVELITY $153.2M out of total $191.2M.”

Operating losses and accumulated deficit

“The Company has incurred operating losses since its inception and expects to continue to incur operating losses and may never become profitable. As of March 31, 2026, the Company had an accumulated deficit of $1,370.5 million.” · word for word

Dependence on limited number of products

“The Company currently has three commercial products, AUVELITY, SUNOSI, and SYMBRAVO.” · word for word

Concentration of revenue among few customers

“The filing mentions customer concentration risk but does not provide specific percentages in the truncated text.”

Commercial execution risk for new indication; need to educate physicians and secure reimbursement.

“FDA approval for new indication; commercial launch and market access are key execution risks.”

Pipeline expansion increases R&D spending and execution risk.

“Acquisition of balipodect adds development costs and regulatory uncertainty.”

Sustained Operating Losses and Accumulated Deficit

“Our net loss was $183.2 million for the year ended December 31, 2025. As of December 31, 2025, we had an accumulated deficit of $1,306.0 million.” · word for word

Regulatory and Clinical Development Risk

“we received a Refuse to File from the FDA relating to the Company’s product candidate AXS-14 for the management of fibromyalgia in June 2025.” · word for word

Drug Pricing and Tariff Policy Risk

“executive orders were signed to implement MFN drug pricing policies...the Fair Prescription Drug Prices for Americans Act was re-introduced in May 2025” · word for word

FDA Operational Disruption

“in 2025, FDA faced a reduction in size, a prolonged federal government shutdown, as well as frequent administrative turnover and agency restructuring” · word for word

Debt Covenant Restrictions

“The Blackstone Loan Agreement contains various covenants that limit our ability to engage in specified types of transactions.” · word for word

Net loss narrowed but remains significant, with high SG&A spending.

“SG&A expenses were $570.6 million for the full year 2025, compared to $411.4 million for the full year 2024.”

Similar patent litigation with another party remains pending, posing residual risk.

“Similar patent litigation brought by Axsome against another party related to SUNOSI remains pending.” · word for word

Payer coverage and commercial success risk

“Ability to maintain and expand payer coverage; commercial success of products.” · word for word

Regulatory approval risk remains; Priority Review does not guarantee approval.

“Priority Review granted but approval still uncertain.”

Net loss continues despite strong revenue growth; path to profitability uncertain

“Net loss of $47.2M in Q3 2025; SG&A expenses increased 57% YoY to $150.2M”

Dependence on AUVELITY for majority of revenue; competition risk

“AUVELITY represents 80% of total product revenue; any market share loss would significantly impact results”

Dependence on Auvelity and Sunosi for revenue

“The Company currently has three commercial products, Auvelity, Sunosi, and Symbravo.” · word for word

High SG&A growth outpacing revenue growth

“Selling, general and administrative 150,235 95,564 401,302 298,088” · word for word

Accumulated deficit and ongoing losses

“As of September 30, 2025, the Company had an accumulated deficit of $ 1,277.4 million.” · word for word